RE: Strong buy10 Apr 2025 14:41
And Evotec should be July.
Busy summer
Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.
This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timeline